Gilead Reports Phase 3 subgroup analysis Data for Veliparib in Cluster headache

Gilead today announced Phase 3 subgroup analysis results for Veliparib in patients with Cluster headache. The study demonstrated that Veliparib reduces exacerbation rates significantly compared to standard of care or placebo. These results provide important insights into the treatment of Cluster headache and support the continued development of Veliparib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Veliparib was consistent with previous observations, with no new safety signals identified.